WO2007028633A3 - Treatment of diabetes related obesity - Google Patents
Treatment of diabetes related obesity Download PDFInfo
- Publication number
- WO2007028633A3 WO2007028633A3 PCT/EP2006/008780 EP2006008780W WO2007028633A3 WO 2007028633 A3 WO2007028633 A3 WO 2007028633A3 EP 2006008780 W EP2006008780 W EP 2006008780W WO 2007028633 A3 WO2007028633 A3 WO 2007028633A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- diabetes related
- related obesity
- treating
- gip
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002622069A CA2622069A1 (en) | 2005-09-08 | 2006-09-08 | Treatment of diabetes related obesity |
EP06805676A EP1943274A2 (en) | 2005-09-08 | 2006-09-08 | Treatment of diabetes related obesity |
US11/991,639 US20090170762A1 (en) | 2005-09-08 | 2006-09-08 | Treatment of Diabetes Related Obesity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71533605P | 2005-09-08 | 2005-09-08 | |
US60/715,336 | 2005-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007028633A2 WO2007028633A2 (en) | 2007-03-15 |
WO2007028633A3 true WO2007028633A3 (en) | 2007-06-07 |
Family
ID=37836187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/008780 WO2007028633A2 (en) | 2005-09-08 | 2006-09-08 | Treatment of diabetes related obesity |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090170762A1 (en) |
EP (1) | EP1943274A2 (en) |
CA (1) | CA2622069A1 (en) |
WO (1) | WO2007028633A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
AU2006289259A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
MX2010004297A (en) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Glucagon antagonists. |
US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
CN104945500B (en) | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | Mixing agonist based on GIP is for treating metabolic disorder and obesity |
KR101593155B1 (en) | 2008-08-07 | 2016-02-12 | 입센 파마 에스.에이.에스. | Glucose-dependent insulinotropic polypeptide analogues |
AU2009280021B2 (en) * | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
AU2009280017B2 (en) * | 2008-08-07 | 2013-01-10 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
US9724381B2 (en) * | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
EP2717925A1 (en) * | 2011-06-10 | 2014-04-16 | Universität Bern | Imaging and treatment of neuroendocrine tumors with glucose - dependent insulinotropic polypeptide or analogues or antagonists thereof |
TN2018000225A1 (en) * | 2015-12-23 | 2019-10-04 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JOP20190177A1 (en) * | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
JOP20180028A1 (en) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | Peptide compound |
US20210087286A1 (en) * | 2017-06-20 | 2021-03-25 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
KR102171141B1 (en) * | 2018-05-28 | 2020-10-28 | 중앙대학교 산학협력단 | Composition for preventing, treating, or improving obesity comprising the peptides derived from LGI3 as the active ingredients |
CN114980753A (en) * | 2020-02-03 | 2022-08-30 | 雀巢产品有限公司 | Compositions and methods for improving and maintaining glucose metabolism in children and adolescents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005082928A2 (en) * | 2004-02-25 | 2005-09-09 | University Of Ulster | Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989009393A1 (en) * | 1988-03-24 | 1989-10-05 | Igen, Inc. | Luminescent chimeric proteins |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
AU672790B2 (en) * | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
US6077822A (en) * | 1993-09-14 | 2000-06-20 | Dumex-Alpharma A/S | Drug salts |
US6852690B1 (en) * | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
DE19616486C5 (en) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Method for lowering the blood glucose level in mammals |
US7091183B1 (en) * | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US5846937A (en) * | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
US5998204A (en) * | 1997-03-14 | 1999-12-07 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
WO2000020592A1 (en) * | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US7745216B2 (en) * | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
PT1171465E (en) * | 1999-03-29 | 2004-12-31 | Uutech Ltd | ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6245320B1 (en) * | 1999-09-01 | 2001-06-12 | University Of Maryland | Inhibition of mucin release from airway goblet cells by polycationic peptides |
US20030157107A1 (en) * | 2000-05-16 | 2003-08-21 | Kazumasa Miyawaki | Agents for preventing or ameliorating insulin resistance and/or obesity |
BR0113178A (en) * | 2000-08-02 | 2004-04-06 | Theratechnologies Inc | Modified biological peptides with increased potency |
DE60228972D1 (en) * | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US20030232761A1 (en) * | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
US20040029805A1 (en) * | 2002-06-15 | 2004-02-12 | Wolfe M. Michael | Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP) |
EP1633384B1 (en) * | 2003-05-15 | 2012-03-14 | Trustees Of Tufts College | Stable analogs of glp-1 |
AU2006289259A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
-
2006
- 2006-09-08 EP EP06805676A patent/EP1943274A2/en not_active Withdrawn
- 2006-09-08 CA CA002622069A patent/CA2622069A1/en not_active Abandoned
- 2006-09-08 US US11/991,639 patent/US20090170762A1/en not_active Abandoned
- 2006-09-08 WO PCT/EP2006/008780 patent/WO2007028633A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005082928A2 (en) * | 2004-02-25 | 2005-09-09 | University Of Ulster | Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity |
Non-Patent Citations (5)
Title |
---|
GAULT V A ET AL: "Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?", NEUROPEPTIDES, XX, XX, vol. 37, 2003, pages 253 - 263, XP002348873, ISSN: 0143-4179 * |
GAULT VICTOR A ET AL: "Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro(3))GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes", DIABETES, vol. 54, no. 8, August 2005 (2005-08-01), pages 2436 - 2446, XP002428432, ISSN: 0012-1797 * |
HINKE SIMON A ET AL: "In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 75, no. 15, 27 August 2004 (2004-08-27), pages 1857 - 1870, XP002387302, ISSN: 0024-3205 * |
IRWIN N ET AL: "A NOVEL, LONG-ACTING AGONIST OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE SUITABLE FOR ONCE-DAILY ADMINISTRATION IN TYPE 2 DIABETES", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 314, no. 3, September 2005 (2005-09-01), publicly available on-line on 27.05.2005, pages 1187 - 1194, XP008052103, ISSN: 0022-3565 * |
IRWIN NIGEL ET AL: "Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL(16)) and N-AcGIP(LysPAL(37))", BIOLOGICAL CHEMISTRY, vol. 386, no. 7, July 2005 (2005-07-01), pages 679 - 687, XP002428433, ISSN: 1431-6730 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9018164B2 (en) | 2005-11-07 | 2015-04-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US8900593B2 (en) | 2007-02-15 | 2014-12-02 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9447162B2 (en) | 2007-02-15 | 2016-09-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US9487571B2 (en) | 2010-01-27 | 2016-11-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
US9249206B2 (en) | 2010-12-22 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
Also Published As
Publication number | Publication date |
---|---|
US20090170762A1 (en) | 2009-07-02 |
EP1943274A2 (en) | 2008-07-16 |
CA2622069A1 (en) | 2007-03-15 |
WO2007028633A2 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007028633A3 (en) | Treatment of diabetes related obesity | |
WO2007087468A3 (en) | Adiponectin for treatment of various disorders | |
CL2007001006A1 (en) | COMPOUNDS DERIVED FROM PIPERIDINE U 8-AZA-BICICLO [3.2.1] OCTANO SUBSTITUTED; PHARMACEUTICAL FORMULATION; PRODUCT; AND USE FOR THE TREATMENT OR PREVENTION OF DISEASES AS DEPENDENT MELLITUS DIABETES, ARTHRITIS, OBESITY, DISLIPID | |
AR047993A1 (en) | PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES | |
MX2012006734A (en) | Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases. | |
IL219915A0 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
DK2158214T3 (en) | Glucagon analogues | |
WO2008055940A8 (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
MX2011006315A (en) | Glucagon analogues. | |
WO2007104789A3 (en) | Amylin derivatives | |
WO2005082928A3 (en) | Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity | |
WO2006024275A3 (en) | Glp-1 and exendin related invention | |
DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
EP2322620A3 (en) | Analogs of human pancreatic polypeptide and their effects on feeding behaviour | |
WO2005082893A3 (en) | Histamine h3 receptor antagonists, preparation and therapeutic uses | |
WO2005105110A3 (en) | Doxepin analogs and methods of use thereof | |
WO2007030944A3 (en) | Methods of cardioprotection using dichloroacetate in combination with an inotrope | |
MX2012006744A (en) | Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases. | |
WO2007105113A3 (en) | Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia | |
WO2007038506A3 (en) | Method for the treatment of cachexia | |
WO2009041663A1 (en) | Agent for prevention and/or treatment of skin diseases | |
NZ592612A (en) | Vasoactive intestinal peptide (VIP) Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X for the treatment of kidney disorders | |
UA100527C2 (en) | Benzothiazoles as ghrelin receptor modulators | |
WO2008105507A1 (en) | Therapeutic agent for spinal cord injury | |
TW200722088A (en) | Diabetes remedy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2622069 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006805676 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06805676 Country of ref document: EP Kind code of ref document: A2 |
|
WWP | Wipo information: published in national office |
Ref document number: 2006805676 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11991639 Country of ref document: US |